Christopher A. Klebanoff

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

56h-index24.4kcitations231works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(125), Immunotherapy and Immune Responses(95), Cancer Immunotherapy and Biomarkers(70), Immune Cell Function and Interaction(67), T-cell and B-cell Immunology(39)

Publications230 total

CISH, a key intracellular checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
Communications Biology·2026Open Access
HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity
2025Open Access
The resting and ligand-bound states of the membrane-embedded human T-cell receptor–CD3 complex
Nature Communications·2025· 2 citedOpen Access
Molecular mechanisms of immunogenicity and TCR recognition of NRAS-derived public neoantigens 4770
The Journal of Immunology·2025Open Access
Structural insights and immunogenic enhancement of KRAS neoantigen recognition by TCRs in cancer immunotherapy 4724
The Journal of Immunology·2025Open Access
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy
Nature Cancer·2025· 2 citedOpen Access
110O Pan-cancer mapping of HLA class I loss of heterozygosity in a 50,000 patient cohort reveals prognostic clinical implications for HLA-restricted therapies
Annals of Oncology·2025
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Nature Cancer·2025· 14 citedOpen Access
Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
Journal of Clinical Oncology·2025
CISH, a novel intracellular immune checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
2025Open Access
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
The Lancet Oncology·2025· 32 cited
Abstract CT269: First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint <i>CISH</i> is inhibited
Cancer Research·2025· 1 cited
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
Cell·2025· 24 citedOpen Access
Abstract 3745: Allele-specific HLA LOH frequencies and survival outcomes in cancer: a real-world analysis
Cancer Research·2025
Abstract 4250: Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens across cancers
Cancer Research·2025· 1 cited
Abstract B051: Deletion of the RNA-binding protein PCBP2 sensitizes tumor cells to CD4+ T cell killing
Cancer Immunology Research·2025
Abstract PR011: Immunogenic landscape and therapeutic targeting of mutant NRAS ”public” neoantigens
Cancer Immunology Research·2025
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Nature·2025· 43 citedOpen Access
Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy
Transplantation and Cellular Therapy·2025· 1 cited
page 1 of 12Next →

Frequent Co-authors

Nicholas P. Restifo(36), Luca Gattinoni(28), Douglas C. Palmer(26), Zhiya Yu(19), Steven A. Rosenberg(19), Madhusudhanan Sukumar(15), Yun Ji(14), Rahul Roychoudhuri(14), Pawel Muranski(11), Robert Eil(10), David Clever(10), Paul A. Antony(8), Joseph G. Crompton(8), Steven E. Finkelstein(7), Christian S. Hinrichs(7), Zachary A. Borman(7), Ena Wang(7), Francesco M. Marincola(7), Smita S. Chandran(6), Shashank J. Patel(6)